Cobenfy demonstrated statistically significant improvements in schizophrenia symptoms. Bristol Myers Squibb acquired Karuna Therapeutics' treatment in a $14 billion deal, marking a significant ...

The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers ...

Originally developed by Karuna Therapeutics and named KarXT, BMS inherited the drug as part of a $14bn acquisition, which was finalised in March 2024.

The drug, called Cobenfy, will be sold by Bristol Myers Squibb. It was developed by the biotech company Karuna Therapeutics, which Bristol acquired for $14 billion last year . advertisement ...

N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics. By Frank Vinluan on September 27, 2024 2:19 pm. ... Cobenfy was developed in the labs of Karuna Therapeutics ...

Boston-based Karuna Therapeutics rolled the dice on xanomeline, licensing it from Lilly in 2012. In December of last year, BMS swooped in and bought out Karuna for $14 billion, convinced of KarXT ...

Based largely on Cobenfy’s promise, Bristol Myers Squibb paid $14 billion to acquire the company that developed the drug, Karuna Therapeutics, completing the acquisition March 18.

Investment Overview — Background To Cobenfy Approval — Bristol-Myers Squibb's Buyout Of Karuna. Back in April 2020, I covered a company called Karuna Therapeutics in a note for Seeking Alpha ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new drug. BMS’ first-in ...

Bristol Myers obtained the drug, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics, and is seen as one of the key growth drivers for the drugmaker.

It acquired Mirati Therapeutics, RayzeBio, and Karuna Therapeutics in 2024, spending around $24 billion. Now, with the approval of Cobenfy, which was under Karuna Therapeutics, ...